Not losing weight on Mounjaro 15mg? Here's what's actually happening

The biggest myth: 15mg should mean fast, continuous loss

Many people arrive at 15mg expecting the dose to deliver a steep, unbroken downward line on the scales. That expectation is understandable (the titration schedule builds anticipation) but it is not how the medicine works. In the SURMOUNT-1 trial, published in the New England Journal of Medicine, participants lost an average of around 20–21% of body weight over 72 weeks at the 15mg dose. That is roughly a year and a half of treatment. Embedded in that average are plenty of weeks where the number barely moved. Weight loss on tirzepatide is not a smooth curve; it is a series of drops, pauses and occasional small rises, averaging out over months. Reaching the top dose and experiencing a lull does not mean the medicine has stopped working. It often means your metabolism is catching up with the changes already made.

The NHS patient information for tirzepatide is clear that treatment works alongside a reduced-calorie diet and increased physical activity, not independently of them. That framing matters at every dose, but it matters most at 15mg, where there is no higher rung to climb to.

Biological reasons weight loss slows at the maximum dose

Your body is not passive. As weight falls, your resting metabolic rate adjusts, you burn fewer calories maintaining a smaller body than you did maintaining a larger one. This is sometimes called adaptive thermogenesis, and it is one reason a plateau at 15mg does not always signal a medicine failure. It may simply mean that calorie intake and calorie expenditure have quietly equalised, even though both have fallen.

Stress is another factor that patients underestimate. Elevated cortisol encourages fat storage, particularly around the abdomen, and can blunt the appetite-suppressing effect of GLP-1 receptor activation. Poor sleep compounds this, studies consistently show that sleep restriction raises hunger hormones even when appetite suppression is otherwise in place. One practical check you can do in under a minute: look at your sleep average in your phone's health app for the past two weeks. If you are consistently under seven hours, that data is worth raising with your prescriber.

Muscle mass matters too. If weight loss has included loss of lean tissue (common when protein intake drops too low), your metabolic rate falls further. This is one reason prescribers and dietitians often emphasise protein-rich meals and resistance activity even at the highest dose. It is not about eating more; it is about eating differently.

What is and is not in your control at this dose

Some things are genuinely fixable. Portion awareness drifts over time, early in treatment, severe appetite suppression makes overeating difficult. At 15mg, after months of titration, some appetite creep is normal as the body partially adapts. A brief food diary, even for three or four days, often surfaces patterns that feel invisible day to day: liquid calories, snacks that have become habitual, portion sizes that have quietly expanded.

Other factors are worth discussing rather than self-managing. Certain medications (some antidepressants, corticosteroids, beta-blockers) are associated with weight gain or resistance to loss. Thyroid function is another variable that can shift quietly, especially in women over 40. These are not reasons to stop Mounjaro; they are reasons to have a proper clinical conversation. If you started treatment elsewhere and are considering transferring to a service with stronger ongoing support, our clinical team at nume reviews each case individually before continuing any dose.

Questions about whether your current dose is right, whether a co-medication could be contributing, or how to interpret a six-month result are exactly what ongoing prescriber access is for. The prescribing team at nume offers aftercare seven days a week for this reason.

When to take stock, and what NICE guidance says

There is a formal clinical review point built into NICE's recommendation for tirzepatide. Under NICE Technology Appraisal 1026, if a person has not lost at least 5% of their initial body weight after six months at the highest tolerated dose, continuing treatment is reviewed. This threshold exists because the medicine's benefit-to-burden ratio shifts when the response is minimal. It does not mean treatment automatically stops; it means the prescriber reassesses the full picture.

If you are not near that threshold (if you have lost weight but the pace has slowed) that is a different conversation. A plateau after meaningful loss is not the same as a non-response. Many people find that small adjustments to meal composition, activity type, or sleep habits break a stall without any change to the medicine itself.

The same experience at lower doses has its own specific considerations, and if you are wondering why you are not losing weight on Mounjaro 2.5mg, why the 5mg dose does not seem to be working, what can stall progress at 7.5mg, or why weight loss slows at 10mg, each of those doses has a dedicated page covering the patterns specific to that stage; readers who plateaued earlier in titration can also find a fuller breakdown of what happens at 12.5mg or, for those curious about patterns across the whole titration schedule, our Mounjaro overview covers how response typically develops from the starter dose onwards.

If you are not yet on a full assessment with a clinician who can review your progress data, check your eligibility with our prescribers, the consultation is free, and the same prescriber who assesses you stays involved if treatment is approved.